Concepts (91)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neoplasms, Complex and Mixed | 1 | 2014 | 43 | 0.490 |
Why?
|
| Pleural Neoplasms | 3 | 2023 | 470 | 0.450 |
Why?
|
| Mesothelioma | 3 | 2023 | 544 | 0.420 |
Why?
|
| Gastric Mucosa | 1 | 2014 | 613 | 0.380 |
Why?
|
| Hallux | 1 | 2008 | 3 | 0.330 |
Why?
|
| Foot Diseases | 1 | 2008 | 52 | 0.320 |
Why?
|
| Neuroendocrine Tumors | 1 | 2014 | 634 | 0.320 |
Why?
|
| Stomach Neoplasms | 1 | 2014 | 2278 | 0.210 |
Why?
|
| Biomimetics | 1 | 2021 | 33 | 0.200 |
Why?
|
| Lung Transplantation | 1 | 2022 | 359 | 0.160 |
Why?
|
| B7-H1 Antigen | 2 | 2023 | 1022 | 0.150 |
Why?
|
| Lung Neoplasms | 3 | 2023 | 11538 | 0.130 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2021 | 8873 | 0.130 |
Why?
|
| Peptide Fragments | 1 | 2021 | 1271 | 0.130 |
Why?
|
| Cisplatin | 1 | 2021 | 2432 | 0.120 |
Why?
|
| Transcriptome | 1 | 2021 | 1859 | 0.110 |
Why?
|
| Diagnosis, Differential | 2 | 2014 | 4744 | 0.110 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2021 | 2488 | 0.100 |
Why?
|
| Biomarkers, Tumor | 2 | 2021 | 10331 | 0.100 |
Why?
|
| Skin Neoplasms | 1 | 2008 | 4654 | 0.100 |
Why?
|
| Adenocarcinoma | 3 | 2022 | 7789 | 0.100 |
Why?
|
| Receptors, Progesterone | 1 | 2017 | 1392 | 0.100 |
Why?
|
| Melanoma | 1 | 2008 | 5317 | 0.100 |
Why?
|
| Genomics | 1 | 2021 | 2738 | 0.090 |
Why?
|
| Receptor, ErbB-2 | 2 | 2017 | 2518 | 0.090 |
Why?
|
| Gene Expression Profiling | 1 | 2021 | 5159 | 0.090 |
Why?
|
| Receptors, Estrogen | 1 | 2017 | 2086 | 0.090 |
Why?
|
| Esophageal Neoplasms | 1 | 2021 | 3168 | 0.080 |
Why?
|
| Prostate | 1 | 2012 | 1088 | 0.070 |
Why?
|
| Disease Progression | 1 | 2014 | 6682 | 0.060 |
Why?
|
| Middle Aged | 6 | 2021 | 86204 | 0.050 |
Why?
|
| Breast Neoplasms | 2 | 2017 | 15694 | 0.050 |
Why?
|
| Neoadjuvant Therapy | 3 | 2023 | 4975 | 0.050 |
Why?
|
| Tumor Microenvironment | 2 | 2023 | 2864 | 0.050 |
Why?
|
| Carcinoma, Large Cell | 1 | 2021 | 94 | 0.050 |
Why?
|
| Humans | 11 | 2023 | 261506 | 0.050 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2008 | 1415 | 0.050 |
Why?
|
| Neoplasm, Residual | 2 | 2017 | 1656 | 0.050 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2021 | 367 | 0.050 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2021 | 198 | 0.050 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2021 | 275 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2021 | 476 | 0.040 |
Why?
|
| CTLA-4 Antigen | 1 | 2023 | 657 | 0.040 |
Why?
|
| Aged | 4 | 2021 | 70117 | 0.040 |
Why?
|
| Phenotype | 2 | 2021 | 6295 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2021 | 1313 | 0.040 |
Why?
|
| Retrospective Studies | 3 | 2017 | 37905 | 0.040 |
Why?
|
| Apoptosis | 2 | 2021 | 7591 | 0.040 |
Why?
|
| Epirubicin | 1 | 2017 | 157 | 0.040 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2021 | 406 | 0.040 |
Why?
|
| Macrophages | 1 | 2022 | 1304 | 0.030 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2021 | 716 | 0.030 |
Why?
|
| Survival Rate | 2 | 2020 | 12221 | 0.030 |
Why?
|
| Prostatic Neoplasms | 1 | 2012 | 5767 | 0.030 |
Why?
|
| Disease-Free Survival | 2 | 2017 | 10001 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2021 | 1493 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2017 | 15862 | 0.030 |
Why?
|
| Ultrasonography, Mammary | 1 | 2017 | 380 | 0.030 |
Why?
|
| Trastuzumab | 1 | 2017 | 696 | 0.030 |
Why?
|
| Adult | 3 | 2017 | 77950 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2021 | 5395 | 0.030 |
Why?
|
| Male | 3 | 2014 | 123000 | 0.030 |
Why?
|
| Fluorouracil | 1 | 2017 | 1944 | 0.030 |
Why?
|
| Prognosis | 2 | 2020 | 21713 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2017 | 1987 | 0.020 |
Why?
|
| Female | 3 | 2017 | 141928 | 0.020 |
Why?
|
| Paclitaxel | 1 | 2017 | 1996 | 0.020 |
Why?
|
| Cyclophosphamide | 1 | 2017 | 3001 | 0.020 |
Why?
|
| Doxorubicin | 1 | 2017 | 3005 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2022 | 8223 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2017 | 3890 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2021 | 7226 | 0.020 |
Why?
|
| Biopsy, Needle | 1 | 2012 | 1363 | 0.020 |
Why?
|
| Neoplasm Grading | 1 | 2012 | 1742 | 0.020 |
Why?
|
| Prostatectomy | 1 | 2012 | 962 | 0.020 |
Why?
|
| Infant | 1 | 2022 | 13310 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2021 | 14551 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2022 | 16273 | 0.020 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2021 | 5437 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2012 | 1863 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2017 | 6869 | 0.020 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2021 | 5319 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2012 | 4892 | 0.010 |
Why?
|
| Time Factors | 1 | 2017 | 12926 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2017 | 12873 | 0.010 |
Why?
|
| Adolescent | 1 | 2022 | 31252 | 0.010 |
Why?
|
| Child | 1 | 2022 | 29154 | 0.010 |
Why?
|
| Mice | 1 | 2021 | 34495 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2021 | 14289 | 0.010 |
Why?
|
| Animals | 1 | 2021 | 59536 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2012 | 29902 | 0.010 |
Why?
|